PROF Archives - BioTuesdays

Developments

Telix in PSMA collaboration with Profound Medical and other prostate cancer therapy players

Telix Pharmaceuticals (ASX:TLX, NASDAQ:TLX) announced that it has entered into letters of intent to pursue collaborations to explore the investigational use of its PSMA-PET imaging agents Gozellix (kit for the...

May 15, 2026

Developments

SIR highlights Profound’s CAPTAIN study results showing faster recovery with TULSA v robotic prostate surgery

The Society of Interventional Radiology (SIR) has highlighted the results of Profound Medical’s (NASDAQ: PROF; TSX: PRN) randomized post-market CAPTAIN trial demonstrating that men with localized, intermediate-risk...

April 14, 2026

Developments

Profound congratulates Texas Prostate’s 100th TULSA Procedure milestone

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure performed in Dallas Medical Center’s state-of-the-art MRI suite. “Having...

March 27, 2026

Developments

Trial finds Profound’s TULSA Procedure significantly improves erectile function and continence vs. robotic radical prostatectomy

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic...

March 16, 2026

Developments

INOVAIT honors Profound with 2025/26 Mount Logan Award recognizing Tulsa Procedure for prostate disease

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that it has received the 2025/2026 Mount Logan Award from INOVAIT, the Canadian national network for commercializing breakthroughs in image-guided therapy and AI...

February 12, 2026

Developments

PRO FAMILIA and Profound mark 500 Sonalleve Procedures; expand access to incision-free women’s healthcare

Profound Medical (NASDAQ:PROF; TSX:PRN) announced today that PRO FAMILIA Specialist Hospital in Rzeszów, Poland has completed its 500th Sonalleve Procedure. The MRI-guided therapy provides women with a non-surgical...

February 5, 2026

Developments

Mount Sinai becomes first in NYC to deliver incision-free, MRI-guided prostate treatment with Profound’s TULSA-PRO

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that the world-renowned Mount Sinai Hospital, Metro New York (NYC), has successfully treated its first prostate cancer patient with the TULSA-PRO system. The TULSA...

January 15, 2026

Developments

Profound surpasses 2025 TULSA-PRO installed base goal

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that its TULSA-PRO system installed base reached 78 as of December 31, 2025—exceeding its previously announced goal of 75 installs by year-end 2025. The company’s TULSA...

January 12, 2026

Developments

Johns Hopkins Medicine treats first commercial TULSA-PRO case; Profound marks major milestone as hospital launches iMRI suite to expand access to advanced prostate care

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the company’s TULSA-PRO system. The milestone marks the...

January 6, 2026

Developments

Stanford’s Dr. Ghanouni receives Cum Laude award for RSNA presentation on CAPTAIN trial of TULSA v robotic radical prostatectomy

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that Pejman Ghanouni, MD, PhD, associate professor in the Department of Radiology, Division of Body MRI at Stanford University School of Medicine, has received the...

December 5, 2025

Tag - PROF

Telix in PSMA collaboration with Profound Medical and other prostate cancer therapy players

SIR highlights Profound’s CAPTAIN study results showing faster recovery with TULSA v robotic prostate surgery

Profound congratulates Texas Prostate’s 100th TULSA Procedure milestone

Trial finds Profound’s TULSA Procedure significantly improves erectile function and continence vs. robotic radical prostatectomy

INOVAIT honors Profound with 2025/26 Mount Logan Award recognizing Tulsa Procedure for prostate disease

PRO FAMILIA and Profound mark 500 Sonalleve Procedures; expand access to incision-free women’s healthcare

Mount Sinai becomes first in NYC to deliver incision-free, MRI-guided prostate treatment with Profound’s TULSA-PRO

Profound surpasses 2025 TULSA-PRO installed base goal

Johns Hopkins Medicine treats first commercial TULSA-PRO case; Profound marks major milestone as hospital launches iMRI suite to expand access to advanced prostate care

Stanford’s Dr. Ghanouni receives Cum Laude award for RSNA presentation on CAPTAIN trial of TULSA v robotic radical prostatectomy

Subscribe